Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial ECOG 3612

Title
A Randomized Phase II Trial of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma
Principal Investigator
Timothy Kuzel
Details
  • Status: SUSPENDED
  • Study Type: Therapeutic, Treatment
  • Protocol No:.ECOG 3612
Purpose
The purpose of this research study is to compare the effects, good and/or bad, of ipilimumab or in combination with bevacizumab in treating unresectable advanced melanoma.
Overview
Ipilimumab is the standard treatment for advanced melanoma and it does a good job in treating melanoma (skin cancer). Bevacizumab is an angiogenesis inhibitor, a drug that slows the growth of new blood vessels. It is approved by the U.S. Food & Drug Adminstration(FDA)for treatment of other cancers but it's use in this study is experiment. This study is looking to see if the addition of bevacizumab to ipilimumab can further improve treament of melanoma.
Eligibility
Some of the eligibility criteria include:
  • Particpants must be 18 years of age or older.
  • Participants must have unresectable (can't be removed surgically) advanced melanoma that has not been treated or has only received one treatment.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
There are two groups in this study, Group 1 and Group 2. Participants are randomized (like flipping a coin) into group 1 or 2. Both groups will receive ipilimumab for 3 months which is also referred to as a cycle. Group 2 will also take bevacizumab every 3 weeks. Participants will continue on this study until their disease progresses or the study doctor thinks it is in their best interest to continue.
Contact
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
312.695.1102
cancertrials@northwestern.edu

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Timothy Kuzel

last updated: 24-Nov-14 06:07 AM

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.